Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis

Ryumachi

Volumn 41, Issue 6, 2001, Pages 929-937

  Nakazaki, Satoshi ^a   Murayama, Takashi ^a   Katoh, Siniti ^a  

^a Kanazawa Municipal Hospital   (Japan)

Author keywords

Cytopenia; Life table analysis; Mean corpuscular volume; Methotrexate; Rheumatoid arthritis (RA)

Indexed keywords

METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOPENIA; FEMALE; FEVER; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIFE TABLE; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MOUTH MUCOSA; PANCYTOPENIA; RELAPSE; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTOPENIA;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LEUKOPENIA; MALE; METHOTREXATE; MIDDLE AGED; PANCYTOPENIA; PULSE THERAPY, DRUG; THROMBOCYTOPENIA;

EID: 0035702946     PISSN: 03009157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Life table analysis of 879 treatent episodes with slow acting antirheumatic drugs in community rheumatology practice
2. The epidemiology of drug treatment failure in RA
3. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis
4. The rational use of methotrexate in rheumatoid arthritis and other rheumatic disease
5. Life table analysis of treatment episodes with disease-modifying anti-rheumatic drugs in rheumatid arthritis
6. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice
7. Use of short-term efficacy/toxicity tradeoffs to select secound-line drugs in rheumatoid arthritis: Ametaanalysis of pubilished clinical trials
8. Methotrexate in rheumatoid arthritis: Toxic effects as the major factor in in limiting long-term treatment
9. Guidelines for monitoring drug therapy in rheumatoid arthritis
10. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity
11. Methotrexate and Leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis
12. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatioid arthritis
13. The clinical harmacokinetics of methotrexate
14. Clinical pharmacokinetics of methotrexate
15. Toxicity of low dose methtrexate in rheumatoid arthritis
16. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
17. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis
18. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy
19. Pancytopenia induced by low-dose methotrexate for rheumatoid arthritis
20. Benefit of simultaneous rhG-CSF and methyl-prednisolone 'pulse' therapy for methotrexate-induced bone marrow failure in rheumatoid arthritis
21. Effect of sidium slicylate ad indomethacin on methtorexate-serum albumin binding
22. Renal syndromes associated with nonsteroidal anti-inflammatory drugs